Ryan C. Heniford/LinkedIn
Oct 14, 2025, 05:26
Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
Ryan C. Heniford, Director of Global Business Development and Technical Marketing at Evonik, shared a post on LinkedIn:
”Today is World Thrombosis Day! A reminder that thrombosis prevention isn’t just about medication, it’s also about smarter medical devices.
That’s where Evonik’s Endexo technology comes in.
It’s an innovative passive surface modification that makes catheter surfaces inherently more biocompatible — no coatings, no drugs, no leaching.
Key benefits at a glance:
- Up to 99 % reduction in thrombus accumulation
- Less protein and platelet adhesion → reduced clot risk
- Lower friction for smoother handling and less trauma
- Durable performance because Endexo® is part of the polymer itself
On World Thrombosis Day, it’s worth remembering that every thrombus prevented is a patient protected — and that innovation in materials science plays a crucial role in that.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India